Blood Cancer News and Research

RSS

Anonymous $5.75 million gift will enable UVA to fight against rare blood cancers

A gift of more than $5.75 million from anonymous donors will allow UVA Cancer Center to speed the development of new treatments for rare blood cancers and provide more patients with these cancers access to cutting-edge clinical trials.

29 Aug 2022

New approach using CRISPR can engineer massive quantities of cells for therapeutic applications

A new variation of the CRISPR-Cas9 gene editing system makes it easier to re-engineer massive quantities of cells for therapeutic applications.

25 Aug 2022

The QCOVID4 algorithm developed using data from the Omicron wave identifies those at highest risk of severe COVID-19 outcomes

A recent article illustrated the derivation and validation of the QCOVID4 risk determination algorithm for predicting COVID-19 hospitalization and death risk in England.

18 Aug 2022

People with blood-related cancers more likely to experience COVID breakthrough infections

Individuals with blood-related cancers are more likely to experience a COVID-19 infection even after being vaccinated, a University of Kansas Cancer Center study has found.

12 Aug 2022

New 'decoy receptor' molecules inhibit growth of multiple myeloma and diffuse large B cell lymphoma in mice

Researchers at Stanford University have developed "decoy receptor" molecules that inhibit the growth of both multiple myeloma (MM) and diffuse large B cell lymphoma (DLBCL) in mice.

26 Jul 2022

Improving the immune defenses against blood cancer

For patients with lymphoma, multiple myeloma, or certain types of leukemia, treatment with chimeric antigen receptor T cells (CAR T cells) is sometimes the last chance of overcoming the cancer.

22 Jul 2022

In America, cancer patients endure debt on top of disease

Jeni Rae Peters would make promises to herself as she lay awake nights after being diagnosed with breast cancer two years ago.

9 Jul 2022

Rare Cells Capable of Transforming into Leukemia may Provide new Insight into Leukemic Landscape

In our latest interview, News Medical speaks to Adam G. Schrum, PhD, Associate Professor of Molecular Microbiology & Immunology and Surgery at the University of Missouri, about how dysfunction in an unusual type of thymocyte cell may develop into leukemia in some patients.

8 Jul 2022

Damon Runyon Cancer Research Foundation names five new Damon Runyon Clinical Investigators

The Damon Runyon Cancer Research Foundation has named five new Damon Runyon Clinical Investigators.

6 Jul 2022

Unusual type of thymocyte cells capable of transforming into blood cancer discovered

Dysfunction involving an unusual type of thymocyte cell found in small amounts in every person may be the reason why some people develop a form of leukemia called T-cell acute lymphoblastic leukemia (T-ALL) that affects more than 6,000 Americans each year.

28 Jun 2022

100 million people in America are saddled with health care debt

Elizabeth Woodruff drained her retirement account and took on three jobs after she and her husband were sued for nearly $10,000 by the New York hospital where his infected leg was amputated.

16 Jun 2022

Researchers identify a signature of three genes linked to positive response to blood cancer therapy

Mount Sinai researchers have for the first time identified genes that predict a good response to a vital new therapy for a blood cancer that can have serious side effects for some patients.

16 Jun 2022

Researchers create first comprehensive functional map of genes expressed in human cells

The Human Genome Project was an ambitious initiative to sequence every piece of human DNA. The project drew together collaborators from research institutions around the world, including Whitehead Institute, and was finally completed in 2003.

9 Jun 2022

COVID-19 vaccination may offer less effective and shorter-lasting protection for some cancer patients

A study co-led by the Universities of Oxford, Birmingham and Southampton and the UK Health Security Agency (UKHSA), published in Lancet Oncology today by the UK Coronavirus Cancer Evaluation Project, has found that while COVID-19 vaccination is effective in most cancer patients, the level of protection against COVID-19 infection, hospitalization and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

7 Jun 2022

Genetically engineered immune cells target cancer cells that may be responsible for leukemia relapse

Genetically engineered immune cells successfully target the specific cancer cells that may be responsible for relapse of acute myeloid leukemia (AML), a type of blood cancer, and proved effective in animal models of the disease, according to a preclinical study by investigators at Weill Cornell Medicine.

2 Jun 2022

New study uncovers the impact of genetic mutations on lifelong blood cell production

New research has uncovered how genetic mutations hijack the production of blood cells in different periods of life.

1 Jun 2022

Risk factors for COVID-19 in patients with hematological malignancies

Researchers investigate the risk factors present in individuals suffering from hematological malignancies and COVID-19.

26 May 2022

HMA therapy for patients with myelodysplastic syndrome could potentially activate a sleeping oncogene

Hypomethylating agents (HMA) are currently used as a first-line treatment for patients with myelodysplastic syndrome (MDS) - a group of disorders where there is insufficient production of healthy mature blood cells in the bone marrow - and increasingly in other diseases, but their mechanism of action remains unclear.

26 May 2022

Study brings precision medicine closer to reality for diffuse large B cell lymphoma

DNA mutations are essential to the rapid development of an array of antibody-producing immune cells called B cells that collectively can recognize a vast number of specific targets.

25 May 2022

COVID-19 vaccine effectiveness wanes more quickly in cancer patients, study finds

A study co-led by the Universities of Oxford, Birmingham and Southampton and the UK Health Security Agency (UKHSA), published in Lancet Oncology today by the UK Coronavirus Cancer Evaluation Project, has found that while COVID-19 vaccination is effective in most cancer patients, the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

24 May 2022